论文信息 - Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

Paola Guglielmelli, Arianna Ghirardi, Alessandra Carobbio, Arianna Masciulli, Chiara Maccari, Barbara Mora, Elisa Rumi, Ana Triguero, Maria Chiara Finazzi, Helna Pettersson, Chiara Paoli, Francesco Mannelli, Daniele Vanni, Alessandro Rambaldi, Francesco Passamonti, Alberto Alvarez-Larr an, Bjorn Andreasson, Alessandro M. Vannucchi, and Tiziano Barbui Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, Florence, University of Florence, Italy; Fondazione per la Ricerca Ospedale Maggiore (FROM), Papa Giovanni XXIII Hospital, Bergamo, Italy; Hematology, Aziende Socio Sanitarie Territoriali (ASST) Sette Laghi, University of Insubria, Varese, Italy; Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy; Department of Hematology, Hospital, Clinic de Barcelona, Barcelona, Spain; Department of Oncology-Hematology, University of Milan and Papa Giovanni XXIII Hospital, Bergamo, Italy; Division of Hematology, NU Hospital Group, Uddevalla, Sweden; and Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, Florence, Italy

[1] A. Tefferi,et al. Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management , 2020, American journal of hematology.

[2] J. Dipersio,et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial , 2017, Journal of Hematology & Oncology.

[3] Francisco Cervantes,et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis , 2015, Haematologica.

[4] M. Cazzola,et al. Towards a Better Understanding of Epidemiology, Survival and Treatment in Myeloproliferative Neoplasms: Results of the European Leukemianet Registry (ERNEST study) , 2014 .

[5] M. Cazzola,et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. , 2010, Blood.

[6] R. Mesa,et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[7] D. Rubin,et al. Constructing a Control Group Using Multivariate Matched Sampling Methods That Incorporate the Propensity Score , 1985 .

[8] T Giorgino,et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis , 2017, Leukemia.